lopinavir + ritonavir + lamivudine + efavirenz + tenofovir disoproxil fumarate

This is an oral antiretroviral combination regimen containing five distinct agents used for the treatment of HIV-1 infection. The composition includes: - **Lopinavir** (a protease inhibitor, used only in combination with ritonavir) - **Ritonavir** (a protease inhibitor, used to boost plasma concentrations of lopinavir via CYP3A4 inhibition) - **Lamivudine** (a nucleoside reverse transcriptase inhibitor, NRTI) - **Efavirenz** (a non-nucleoside reverse transcriptase inhibitor, NNRTI) - **Tenofovir disoproxil fumarate** (a nucleotide reverse transcriptase inhibitor, NRTI) Each of these agents targets different enzymatic steps in the HIV replicative cycle, inhibiting maturation, integration, or reverse transcription. This combination is not marketed as a single branded tablet or fixed-dose combination. All ingredients are approved antiretrovirals and are commonly used in various multi-drug regimens for HIV-1 infection[2][3][5]. This five-drug combination reflects a comprehensively suppressive regimen and is used in settings such as salvage therapy or complex clinical cases where resistance or intolerance to standard regimens is present.